Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.

Abstract:

:Forty of the 550 patients (7%) entered to the 11q23 Workshop had secondary (s) acute lymphoblastic leukemia (nine cases), s-acute myeloid leukemia (25 cases, predominantly of FAB type M5), s-acute leukemia unspecified (one case) or s-myelodysplastic syndrome (five cases) following treatment for a primary malignancy. Breast cancer (12 cases) and non-Hodgkin's lymphoma (eight cases) were the most frequent primaries. Twenty-three patients had been treated with either an epipodophyllotoxin (seven patients) or an anthracycline (10 cases) or both (four cases) frequently combined with alkylating agents (12 cases) and with radiotherapy (six cases). Two further patients had alkylating agents and two had radiotherapy alone. Time between diagnosis of the primary and secondary malignancy was between 10 months and 22 years (median 24 months). The incidence of secondary malignancies in 11q23 subgroups was: t(11;19)(q23;p13.1) (33%), t(9;11) (8%), t(4;11) (5.5%), t(10;11)(5%), t (6;11) (3%), del11q23(2%) and 10 patients had a rare 'other' abnormality. No associations were seen between type of prior malignancy and 11q23 subgroup, or between prior malignancy and leukemia subtype. Remission, when achieved (32 patients), was short (median 5 months). Two patients survived following a bone marrow transplant for s-leukemia and s-myelodysplastic syndrome.

journal_name

Leukemia

journal_title

Leukemia

authors

Secker-Walker LM,Moorman AV,Bain BJ,Mehta AB

doi

10.1038/sj.leu.2401021

subject

Has Abstract

pub_date

1998-05-01 00:00:00

pages

840-4

issue

5

eissn

0887-6924

issn

1476-5551

journal_volume

12

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154.

    abstract::Ligation of CD40 on chronic lymphocytic leukemia (CLL) cells induces phenotypic and biochemical changes that facilitate CLL cell-T cell interactions and enhances the sensitivity of CLL cells to clearance by adaptive and innate immune-effector mechanisms. CLL cells can be transduced to express CD40 ligand (CD154) using...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.191

    authors: Wierda WG,Castro JE,Aguillon R,Sampath D,Jalayer A,McMannis J,Prussak CE,Keating M,Kipps TJ

    更新日期:2010-11-01 00:00:00

  • Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.

    abstract::Spliceosome mutations represent a new generation of acquired genetic alterations that affect both myeloid and lymphoid malignancies. A substantial proportion of patients with myelodysplastic syndromes (MDSs) or chronic lymphocytic leukemia (CLL) harbor such mutations, which are often missense in type. Genotype-phenoty...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.86

    authors: Damm F,Nguyen-Khac F,Fontenay M,Bernard OA

    更新日期:2012-09-01 00:00:00

  • Revealing the role of TEL/AML1 for leukemic cell survival by RNAi-mediated silencing.

    abstract::Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, we applied RNA interference to silence TEL/AML1 in le...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.277

    authors: Zaliova M,Madzo J,Cario G,Trka J

    更新日期:2011-02-01 00:00:00

  • Interleukin-6 autoantibodies: possible biological and clinical significance.

    abstract::The pleiotropic cytokines, interleukin (IL)-1 alpha, type I interferons and IL-6 also act on cells involved in antibody production. Somehow the immunologic tolerance to these cytokines is often spontaneously broken--even in healthy individuals. Thus, relatively high concentrations of high affinity IgG antibodies again...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Hansen MB,Svenson M,Diamant M,Abell K,Bendtzen K

    更新日期:1995-07-01 00:00:00

  • IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.

    abstract::Cell lines of myeloid origin have been shown to express interleukin-2 receptors (IL-2R). Here, we demonstrate the expression of IL-2R alpha and IL-R beta on the CML blast cell line K562 by FACS analysis and cross-linking assay. Furthermore, we examined the effect of IL-2 on leukemic progenitor growth, employing K562 a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Dilloo D,Hanenberg H,Lion T,Burdach S

    更新日期:1995-03-01 00:00:00

  • Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

    abstract::Because of their substantial in vitro synergy, we conducted a dose-escalation study of cyclophosphamide (CP) added to 2-chloro-2'-deoxyadenosine (CdA) in patients with previously treated chronic lymphocytic leukemia and non-Hodgkin's lymphoma. CdA was given at a fixed dose (5.6 mg/m2/day) as a 2-h intravenous (i.v.) i...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401783

    authors: Van Den Neste E,Louviaux I,Michaux JL,Delannoy A,Michaux L,Sonet A,Bosly A,Doyen C,Mineur P,André M,Straetmans N,Coche E,Venet C,Duprez T,Ferrant A

    更新日期:2000-06-01 00:00:00

  • Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia.

    abstract::The purpose of this study was to determine the incidence of and pharmacokinetic parameters associated with the development of transient encephalopathy following the administration of high-dose methotrexate and intrathecal chemotherapy in children with acute lymphoblastic leukemia (ALL). Two hundred and fifty-nine chil...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401098

    authors: Rubnitz JE,Relling MV,Harrison PL,Sandlund JT,Ribeiro RC,Rivera GK,Thompson SJ,Evans WE,Pui CH

    更新日期:1998-08-01 00:00:00

  • A paradigm shift in myelodysplastic syndromes.

    abstract::A poorly defined transforming event(s) affects the pluripotential bone marrow (BM) stem cell in myelodysplastic syndromes (MDS), conferring a growth advantage upon it which leads eventually to monoclonal hematopoiesis. The progeny of this transformed ancestor undergo recognizable albeit dysplastic maturation. We propo...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Raza A,Mundle S,Shetty V,Alvi S,Chopra H,Span L,Parcharidou A,Dar S,Venugopal P,Borok R,Gezer S,Showel J,Loew J,Robin E,Rifkin S,Alston D,Hernandez B,Shah R,Kaizer H,Gregory S,Preisler H

    更新日期:1996-10-01 00:00:00

  • Inducible production of macrophage colony-stimulating factor (CSF-1) by malignant and normal human T cells.

    abstract::The CEM-ON malignant T cell line and long-term cultured normal T cells can be induced to release CSF-1 in their culture supernatants. Chemical inducers (PMA + A23187) and, more interestingly, cytokines (tumor necrosis factor alpha (TNF alpha) and interleukin-1 alpha (IL-1 alpha)), as well as physiological (antigen + I...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Praloran V,Gascan H,Papin S,Chevalier S,Trossaërt M,Boursier MC

    更新日期:1990-06-01 00:00:00

  • Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.

    abstract::We explored the association between bone marrow plasma cells (BMPCs) and disease presentation and outcome among 1574 AL patients. Three BMPC groups were formulated: <5% (n = 231, 15% of study population), 5-19% (n = 1045, 66%), and ≥20% (n = 298, 19%). Heart and renal involvement were more and less prevalent, respecti...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0655-x

    authors: Muchtar E,Gertz MA,Kourelis TV,Sidana S,Go RS,Lacy MQ,Buadi FK,Dingli D,Hayman SR,Kapoor P,Leung N,Fonder A,Hobbs M,Lisa Hwa Y,Gonsalves W,Warsame R,Russell S,Lust JA,Lin Y,Zeldenrust S,Rajkumar SV,Kyle RA,Kum

    更新日期:2020-04-01 00:00:00

  • A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

    abstract::The use of darbepoetin alfa to treat anemia in patients with lower-risk myelodysplastic syndromes (MDS) was evaluated in a phase 3 trial. Eligible patients had low/intermediate-1 risk MDS, hemoglobin ⩽10 g/dl, low transfusion burden and serum erythropoietin (EPO) ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.192

    authors: Platzbecker U,Symeonidis A,Oliva EN,Goede JS,Delforge M,Mayer J,Slama B,Badre S,Gasal E,Mehta B,Franklin J

    更新日期:2017-09-01 00:00:00

  • Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery.

    abstract::Membrane-derived vesicles (MV) are released from the surface of activated eucaryotic cells and exert pleiotropic effects on surrounding cells. Since the maintenance of pluripotency and undifferentiated propagation of embryonic stem (ES) cells in vitro requires tight cell to cell contacts and effective intercellular si...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404132

    authors: Ratajczak J,Miekus K,Kucia M,Zhang J,Reca R,Dvorak P,Ratajczak MZ

    更新日期:2006-05-01 00:00:00

  • A tumor suppressor and oncogene: the WT1 story.

    abstract::The Wilms' tumor 1 (WT1) gene encodes a transcription factor important for normal cellular development and cell survival. The initial discovery of WT1 as the causative gene in an autosomal-recessive condition identified it as a tumor suppressor gene whose mutations are associated with urogenital disease and the develo...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404624

    authors: Yang L,Han Y,Suarez Saiz F,Minden MD

    更新日期:2007-05-01 00:00:00

  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract::RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0603-9

    authors: Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期:2020-03-01 00:00:00

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

    abstract::Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathological entity with dif...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2012.336

    authors: Fernández de Larrea C,Kyle RA,Durie BG,Ludwig H,Usmani S,Vesole DH,Hajek R,San Miguel JF,Sezer O,Sonneveld P,Kumar SK,Mahindra A,Comenzo R,Palumbo A,Mazumber A,Anderson KC,Richardson PG,Badros AZ,Caers J,Cavo M,Le

    更新日期:2013-04-01 00:00:00

  • Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

    abstract::To determine the clinical significance of minimal residual disease (MRD) in patients with prognostically relevant subtypes of childhood acute lymphoblastic leukemia (ALL), we analyzed data from 488 patients treated in St Jude Total Therapy Study XV with treatment intensity based mainly on MRD levels measured during re...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.234

    authors: Pui CH,Pei D,Raimondi SC,Coustan-Smith E,Jeha S,Cheng C,Bowman WP,Sandlund JT,Ribeiro RC,Rubnitz JE,Inaba H,Gruber TA,Leung WH,Yang JJ,Downing JR,Evans WE,Relling MV,Campana D

    更新日期:2017-02-01 00:00:00

  • Interleukin-2 and antibody to the T cell receptor regulate proliferation of a radiation leukemia virus-transformed T cell lymphoma.

    abstract::In this report, a Radiation leukemia virus-transformed murine T cell lymphoma is described which is dependent on the interleukin-2 (IL-2) growth factor for proliferation under single cell conditions of growth. It was isolated from a C57BL mouse which had been primed with the Radiation leukemia virus-induced thymoma, C...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: O'Neill HC

    更新日期:1988-02-01 00:00:00

  • Infantile leukemia and soybeans--a hypothesis.

    abstract::Recent molecular-genetic studies have revealed that in the majority of patients with secondary leukemia induced by topoisomerase II (topo II) inhibitors and also with infantile acute leukemia (IAL), the breakpoints are clustered within scaffold attachment regions (SARs) of 3'-MLL-bcr near exon 9. Genistein, abundant i...

    journal_title:Leukemia

    pub_type: 社论

    doi:10.1038/sj.leu.2401344

    authors: Abe T

    更新日期:1999-03-01 00:00:00

  • Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.

    abstract::This report documents the follow-up information on 69 hairy cell leukemia (HCL) patients treated with interferon alpha-2b (IFN) as primary treatment from 1983-86. Follow-up through October 1991 shows only 11 patients have died. Forty-one of the 57 patients completing the intended 12 or more months of initial IFN treat...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Golomb HM,Ratain MJ,Mick R,Daly K

    更新日期:1992-11-01 00:00:00

  • Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

    abstract::Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patien...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/s41375-020-0805-1

    authors: Cortes JE,Jiang Q,Wang J,Weng J,Zhu H,Liu X,Hochhaus A,Kim DW,Radich J,Savona M,Martin-Regueira P,Sy O,Gurnani R,Saglio G

    更新日期:2020-08-01 00:00:00

  • Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

    abstract::The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.160

    authors: Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

    更新日期:2013-01-01 00:00:00

  • Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens.

    abstract::Reduced-intensity conditioning (RIC) regimens have been increasingly used as an alternative to conventional myeloablative conditioning (MAC) regimens for elderly patients, for patients medically infirm to qualify for conventional allogeneic stem cell transplantation (SCT), and for disorders in which traditional MAC-SC...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404681

    authors: Jiménez M,Ercilla G,Martínez C

    更新日期:2007-08-01 00:00:00

  • Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

    abstract::In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402780

    authors: Magnac C,Porcher R,Davi F,Nataf J,Payelle-Brogard B,Tang RP,Oppezzo P,Lévy V,Dighiero G,Ajchenbaum-Cymbalista F

    更新日期:2003-01-01 00:00:00

  • Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years.

    abstract::Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-M0 by FAB Cooperative Study Group in 1991. Among the ...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2401521

    authors: Huang SY,Tang JL,Jou ST,Tsay W,Hu CH,Lin DT,Lin KS,Lin KS,Wang CH,Chen YC,Shen MC,Tien HF

    更新日期:1999-10-01 00:00:00

  • Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

    abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402599

    authors: Munshi NC,Tricot G,Desikan R,Badros A,Zangari M,Toor A,Morris C,Anaissie E,Barlogie B

    更新日期:2002-09-01 00:00:00

  • Terminal deoxynucleotidyl transferase positive subpopulations occur in the majority of ANLL: implications for the detection of minimal disease.

    abstract::A series of 60 acute nonlymphocytic leukemias (ANLL) was analyzed for the expression of terminal deoxynucleotidyl transferase (TdT). The detected TdT+ cells were studied in detail by use of double marker analyses for TdT and differentiation markers, such as myeloid markers (CD13 and CD33), B cell markers, T cell marke...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Adriaansen HJ,van Dongen JJ,Kappers-Klunne MC,Hählen K,van 't Veer MB,Wijdenes-de Bresser JH,Holdrinet AC,Harthoorn-Lasthuizen EJ,Abels J,Hooijkaas H

    更新日期:1990-06-01 00:00:00

  • AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture.

    abstract::The peptide AcSDKP, isolated from fetal calf bone marrow, is able to prevent DNA synthesis in mouse CFU-S in vivo and in vitro. The molecule is demonstrated here to be constitutively produced in mice and synthesized by bone marrow cells in long term culture. ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Wdzieczak-Bakala J,Fache MP,Lenfant M,Frindel E,Sainteny F

    更新日期:1990-03-01 00:00:00

  • p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.

    abstract::The p210 bcr-abl fusion protein tyrosine kinase oncogene has been implicated in the pathogenesis of chronic granulocytic leukemia (CGL). Specific intracellular functions performed by p210 bcr-abl have recently been delineated. We considered the possibility that p210 bcr-abl may also regulate the abundance of inosine 5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gharehbaghi K,Burgess GS,Collart FR,Litz-Jackson S,Huberman E,Jayaram HN,Boswell HS

    更新日期:1994-08-01 00:00:00

  • Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.

    abstract::Mantle cell lymphoma represent a clinicopathologically distinct entity of malignant non-Hodgkin's lymphoma (NHL) and are characterized by a specific chromosomal translocation t(11;14)(q13;q32) involving the cyclin D1 gene also designated as bcl-1/PRAD1 gene on chromosome 11 and the heavy chain immunoglobulin joining r...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401172

    authors: Pott C,Tiemann M,Linke B,Ott MM,von Hofen M,Bolz I,Hiddemann W,Parwaresch R,Kneba M

    更新日期:1998-10-01 00:00:00

  • Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation.

    abstract::Acute myeloid leukemia (AML) involves a block in terminal differentiation of the myeloid lineage and uncontrolled proliferation of a progenitor state. Using phorbol myristate acetate (PMA), it is possible to overcome this block in THP-1 cells (an M5-AML containing the MLL-MLLT3 fusion), resulting in differentiation to...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.246

    authors: Forrest AR,Kanamori-Katayama M,Tomaru Y,Lassmann T,Ninomiya N,Takahashi Y,de Hoon MJ,Kubosaki A,Kaiho A,Suzuki M,Yasuda J,Kawai J,Hayashizaki Y,Hume DA,Suzuki H

    更新日期:2010-02-01 00:00:00